Chemotherapy-Induced Cardiotoxicity Treatment Market Segmented By Drug type such as Dexrazoxane hydrochloride, ACE inhibitors, Beta-blockers, Diuretics, Digoxin and Vasodilators
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP29422
Chemotherapy-induced cardiotoxicity treatment refers to the damage of heart muscles due to intake of chemotherapy drugs. Due to cardiotoxicity, the heart is not able to pump the blood properly to all the parts of the body. Cardiotoxicity may also lead to cardiomyopathy. Cardiomyopathy is caused mainly due to the intake of chemotherapy drugs.
Cardiomyopathy can also be caused due to viruses, high blood pressure, vitamin B deficiency or genetic defects. There can be many other factors causing cardiomyopathy. Long term usage of alcohol is also a risk factor, which can lead to cardiotoxicity. The symptoms of chemotherapy- induced cardiotoxicity include fatigue, cough, bloating etc.
Rapidly increasing prevalence of cancer is the major factor, increasing the growth of chemotherapy-induced cardiotoxicity treatment market. Increasing healthcare expenditure, is an important factor, increasing the growth of chemotherapy-induced cardiotoxicity treatment market.
Other factors such as increasing healthcare awareness, increasing number of hospitals increasing population etc. can increase the growth of chemotherapy-induced cardiotoxicity treatment market. Increasing research and developmental activities, is also one of the important factors leading to the growth of chemotherapy-induced cardiotoxicity treatment market.
Increasing number of research laboratories, can contribute towards the growth of chemotherapy- induced cardiotoxicity market. The increasing government funding for healthcare activities, especially for cancer treatment and research can increase the growth of chemotherapy-induced cardiotoxicity treatment market.
An upsurge in the demand of personalized medicine, is a factor which can fuel the growth of chemotherapy-induced cardiotoxicity treatment market.
Lack of awareness in some of the emerging regions, is a factor which can hinder the growth of chemotherapy-induced cardiotoxicity treatment market. Poor availability of drugs, can also hinder the growth of chemotherapy-induced cardiotoxicity treatment market.
|
Drug type |
|
|
Distribution channels |
|
Geographically, global chemotherapy-induced cardiotoxicity treatment market has been segmented into key regions i.e. North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa. North America is expected to hold the maximum revenue share in the global chemotherapy-induced cardiotoxicity treatment market due the availability of advanced healthcare facilities and new medical devices and drugs.
Also, North America has a well-established healthcare infrastructure. Europe is expected to hold a significant share in global Chemotherapy-induced cardiotoxicity treatment market because of the increasing prevalence of cancer. The chemotherapy-induced cardiotoxicity treatment market in Asia Pacific is expected to grow at a significant growth due to the increasing population and increasing prevalence of cancer.
The chemotherapy-induced cardiotoxicity treatment market is highly fragmented. Some of the players identified in the global Chemotherapy-induced cardiotoxicity treatment market are Pfizer, Merck, Bristol-Myers Squibb, GSK, Novartis, Teva Pharmaceuticals, Sanofi, Aton Pharma, Roche and many more.
To know more about delivery timeline for this report Contact Sales
